These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Experimental study of the protective activity of vaccines made from 7 Pseudomonas aeruginosa immunotypes]. Kholodkova EV; Fedotova IuM; Stanislavskiĭ ES Zh Mikrobiol Epidemiol Immunobiol; 1987 Aug; (8):47-50. PubMed ID: 2446445 [TBL] [Abstract][Full Text] [Related]
8. [Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine]. Moroz AF; Antsiferova NG; Radkevich SA; Mishina VS Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):74-80. PubMed ID: 6800165 [TBL] [Abstract][Full Text] [Related]
9. [Cell-free pseudomonas vaccine. I. Enzyme properties and virulence of strains of P. aeruginosa; protective activity of their water-soluble antigens]. Stanislavskiĭ ES; Zhvanetskaia MI; Mashilova GM; Gladus MA Zh Mikrobiol Epidemiol Immunobiol; 1980 Aug; (8):66-72. PubMed ID: 6778035 [TBL] [Abstract][Full Text] [Related]
17. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100 [TBL] [Abstract][Full Text] [Related]
18. Effect of active and passive immunization on the development of experimental Pseudomonas aeruginosa pyelonephritis in mice. Petit JC; Sicard D; Bayo S; Daguet GL Can J Microbiol; 1981 Jan; 27(1):93-7. PubMed ID: 6783287 [TBL] [Abstract][Full Text] [Related]